KD Logo

News: Marinus Pharmaceuticals Inc’s CHIEF COMMERCIAL OFFICER Shafer Christina reduceds 2,153 shares

Marinus Pharmaceuticals Inc’s recently made public that its CHIEF COMMERCIAL OFFICER Shafer Christina unloaded Company’s shares for reported $20583.0 on Feb 20 ’24. In the deal valued at $9.56 per share,2,153 shares were sold. As a result of this transaction, Shafer Christina now holds 60,308 shares worth roughly $81415.8.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, MANNING MARTHA E sold 1,894 shares, generating $18,126 in total proceeds. Upon selling the shares at $9.57, the SVP, GEN. COUNSEL & CORP. SEC. now owns 52,966 shares.

Before that, Braunstein Scott sold 11,850 shares. Marinus Pharmaceuticals Inc shares valued at $117,789 were divested by the CHAIRMAN AND CEO at a price of $9.94 per share. As a result of the transaction, Braunstein Scott now holds 223,512 shares, worth roughly $0.3 million.

Robert W. Baird downgraded its Marinus Pharmaceuticals Inc [MRNS] rating to a Neutral from a an Outperform in a research note published on April 16, 2024; the price target was decreased to $2 from $20. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who decreased its forecast for the stock in mid April from “an Outperform” to “a Sector perform”. Oppenheimer also remained covering MRNS and has decreased its forecast on August 11, 2023 with a “Perform” recommendation from previously “an Outperform” rating. RBC Capital Mkts started covering the stock on January 20, 2023. It rated MRNS as “an Outperform”.

Price Performance Review of MRNS

On Monday, Marinus Pharmaceuticals Inc [NASDAQ:MRNS] saw its stock jump 1.50% to $1.35. Over the last five days, the stock has lost -8.78%. Marinus Pharmaceuticals Inc shares have fallen nearly -87.58% since the year began. Nevertheless, the stocks have fallen -85.42% over the past one year. While a 52-week high of $11.26 was reached on 01/08/24, a 52-week low of $1.11 was recorded on 04/16/24. SMA at 50 days reached $5.6913, while 200 days put it at $7.6098. A total of 0.92 million shares were traded, compared to the trading of 2.06 million shares in the previous session.

Levels Of Support And Resistance For MRNS Stock

The 24-hour chart illustrates a support level at 1.3133, which if violated will result in even more drops to 1.2767. On the upside, there is a resistance level at 1.4033. A further resistance level may holdings at 1.4567. The Relative Strength Index (RSI) on the 14-day chart is 18.38, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0771, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.33%. Stochastics %K at 5.74% indicates the stock is a buying.

The most recent change occurred on September 30, 2020 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.

Most Popular